{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:26Z","timestamp":1786985246788,"version":"build-2736575974"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20H160028"],"award-info":[{"award-number":["LY20H160028"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017054","name":"National Natural Science Foundation of China Zhejiang Joint Fund for the Integration of Industrialization and Informatization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114712","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T07:09:22Z","timestamp":1681715362000},"page":"114712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies"],"prefix":"10.1016","volume":"162","author":[{"given":"Tianye","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114712_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.114712_bib2","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.114712_bib3","first-page":"19","article-title":"Epithelial ovarian cancer: providing evidence of predisposition genes","author":"Shah","year":"2022","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.biopha.2023.114712_bib4","first-page":"19","article-title":"Non-epithelial ovarian cancers: how much do we really know?","author":"Cheung","year":"2022","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.biopha.2023.114712_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2017.10.007","article-title":"Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects","volume":"120","author":"Boussios","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2023.114712_bib6","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-19-3797","article-title":"Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines","volume":"26","author":"Tischkowitz","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib7","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.114712_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40364-021-00310-y","article-title":"Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study","volume":"9","author":"Yi","year":"2021","journal-title":"Biomark. Res"},{"key":"10.1016\/j.biopha.2023.114712_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.biopha.2023.114712_bib10","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.21037\/atm-20-1683","article-title":"Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?","volume":"8","author":"Moschetta","year":"2020","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib12","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.114712_bib13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114712_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114712_bib15","first-page":"169","volume":"393","author":"Cohen","year":"2019","journal-title":"Cerv. Cancer Lancet"},{"key":"10.1016\/j.biopha.2023.114712_bib16","first-page":"8","article-title":"Human papilloma virus-associated cervical cancer and health disparities","author":"Olusola","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.114712_bib17","first-page":"12","article-title":"HPV and cervical cancer: a review of epidemiology and screening uptake in the UK","author":"Choi","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.biopha.2023.114712_bib18","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2023.114712_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40364-022-00428-7","article-title":"Cervical cancer heterogeneity: a constant battle against viruses and drugs","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark. Res"},{"key":"10.1016\/j.biopha.2023.114712_bib21","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib22","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2023.114712_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114712_bib25","first-page":"14","article-title":"BRCA mutations in ovarian and prostate cancer: bench to bedside","author":"Boussios","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114712_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114712_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41556-021-00764-0","article-title":"POL\u03b8-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis","volume":"23","author":"Llorens-Agost","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114712_bib28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114712_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.tig.2021.03.001","article-title":"Nonhomologous end joining: new accessory factors fine tune the machinery","volume":"37","author":"Ghosh","year":"2021","journal-title":"Trends Genet"},{"key":"10.1016\/j.biopha.2023.114712_bib30","first-page":"78","article-title":"Targeting DNA damage response pathways in cancer. Nat Rev Cancer","volume":"23","author":"Groelly","year":"2023"},{"key":"10.1016\/j.biopha.2023.114712_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2022.01.037","article-title":"Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors","volume":"166","author":"Paulet","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Sci. (N. Y., NY)"},{"key":"10.1016\/j.biopha.2023.114712_bib33","doi-asserted-by":"crossref","first-page":"23234","DOI":"10.1074\/jbc.M002429200","article-title":"ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose)","volume":"275","author":"Oei","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114712_bib34","first-page":"81","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2023.114712_bib35","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114712_bib36","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2023.114712_bib37","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","article-title":"An open-label, multicenter, single-arm, phase ii study of fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian cancer","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.114712_bib39","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib40","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib41","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrclinonc.2016.207","article-title":"Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated disease","volume":"14","author":"Killock","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature16481","article-title":"Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53","volume":"529","author":"Martinez-Zapien","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114712_bib44","first-page":"13","article-title":"Genomic Signatures in HPV-Associated Tumors","author":"Hussain","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2023.114712_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/0008-5472.CAN-19-1036","article-title":"Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer","volume":"80","author":"Xiao","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","article-title":"The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-021-00990-z","article-title":"Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer","volume":"14","author":"Bonazzi","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.biopha.2023.114712_bib48","first-page":"10","article-title":"Applications of proteomics in ovarian cancer: dawn of a new era","author":"Ghose","year":"2022","journal-title":"Proteomes"},{"issue":"1","key":"10.1016\/j.biopha.2023.114712_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2023.114712_bib50","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib51","doi-asserted-by":"crossref","unstructured":"Fugger K.A.-O., Bajrami I.A.-O., Silva Dos Santos M.A.-O., Young S.A.-O., Kunzelmann S.A.-O., Kelly G.A.-O. et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 372(6538): 156\u2013165.","DOI":"10.1126\/science.abb4542"},{"key":"10.1016\/j.biopha.2023.114712_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2023.114712_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","article-title":"Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114712_bib56","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"issue":"585\u2013599","key":"10.1016\/j.biopha.2023.114712_bib57","article-title":"Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold","volume":"178","author":"Vredevoogd","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114712_bib58","doi-asserted-by":"crossref","first-page":"k3529","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2023.114712_bib59","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib61","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cam4.3718","article-title":"Safety and Efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.biopha.2023.114712_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705096","article-title":"Anti-PD-1 and Anti-PD-L1 in head and neck cancer: a network meta-analysis","volume":"12","author":"Botticelli","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib63","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib64","article-title":"A Signature-Based classification of gastric cancer that stratifies tumor immunity and predicts responses to PD-1 Inhibitors","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152212","article-title":"Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice","volume":"227","author":"Tang","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.biopha.2023.114712_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib70","first-page":"19","article-title":"Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer","author":"Revythis","year":"2022","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.biopha.2023.114712_bib71","first-page":"10","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002800050646","article-title":"Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial","volume":"40","author":"Martin","year":"1997","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2023.114712_bib73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12916-022-02605-9","article-title":"Bifunctional anti-PD-L1\/TGF-\u03b2RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.biopha.2023.114712_bib74","first-page":"8","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort","author":"Cho","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib75","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in second-line treatment of patients With NSCLC: results from an expansion cohort of a phase 1 Trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib76","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11523-021-00810-9","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF\u03b2 and PD-L1, in patients with esophageal squamous cell carcinoma: results from a phase 1 cohort in Asia","volume":"16","author":"Lin","year":"2021","journal-title":"Target Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib77","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1093\/oncolo\/oyac254","article-title":"Bintrafusp alfa: a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with pretreated colorectal cancer: results from a phase i trial","volume":"28","author":"Spira","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2023.114712_bib78","first-page":"11","article-title":"Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-\u03b2-trap bifunctional antibody, in patients with advanced solid tumors","author":"Tolcher","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib79","first-page":"8","article-title":"Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer","author":"Yoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib80","doi-asserted-by":"crossref","first-page":"e1292","DOI":"10.1634\/theoncologist.2020-0249","article-title":"Phase I study of the bifunctional fusion protein bintrafusp alfa in asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort","volume":"25","author":"Doi","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2023.114712_bib81","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I Trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib82","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1158\/1078-0432.CCR-19-3806","article-title":"Safety and tolerability of bintrafusp alfa, a bifunctional fusion protein targeting TGF\u03b2 and PD-L1, in asian patients with pretreated recurrent or refractory gastric cancer","volume":"26","author":"Kang","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib83","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-22-0346","article-title":"SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, for recurrent or metastatic cervical cancer: a clinical expansion cohort of a phase i study","volume":"28","author":"Feng","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib84","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 Blockade on PD-1(+) activated T cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Disco"},{"key":"10.1016\/j.biopha.2023.114712_bib85","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-20-3716","article-title":"Safety and Immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2020.07.072","article-title":"A novel bispecific nanobody with PD-L1\/TIGIT dual immune checkpoint blockade","volume":"531","author":"Ma","year":"2020","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2023.114712_bib87","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2217\/fon-2020-1007","article-title":"MAHOGANY: margetuximab combination in HER2+ unresectable\/metastatic gastric\/gastroesophageal junction adenocarcinoma","volume":"17","author":"Catenacci","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib88","first-page":"687","article-title":"Tumor angiogenesis and anti-angiogenic gene therapy for cancer","volume":"16","author":"Li","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2023.114712_bib89","first-page":"9","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib91","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib92","first-page":"20","article-title":"Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)","author":"Hsu","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.114712_bib93","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.biopha.2023.114712_bib94","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114712_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2023.114712_bib96","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.4049\/jimmunol.1601670","article-title":"TCR Signaling and CD28\/CTLA-4 signaling cooperatively modulate T regulatory cell homeostasis","volume":"198","author":"Holt","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib97","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1084\/jem.194.7.893","article-title":"Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells","volume":"194","author":"Doyle","year":"2001","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib98","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.3389\/fimmu.2019.02936","article-title":"Immune checkpoints in circulating and tumor-infiltrating CD4(+) T Cell subsets in colorectal cancer patients","volume":"10","author":"Toor","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib99","first-page":"10","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib100","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib101","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114712_bib102","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2020.11.020","article-title":"Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer","volume":"32","author":"Perets","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib103","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jclinpath-2021-207789","article-title":"Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)","volume":"75","author":"Bolm","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.biopha.2023.114712_bib104","first-page":"10","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","author":"Chiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114712_bib106","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni759","article-title":"Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance","volume":"3","author":"Shimizu","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nri1867","article-title":"The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?","volume":"6","author":"Shevach","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib109","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114712_bib110","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib111","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib112","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib113","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib114","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib115","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib116","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2023.114712_bib117","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib118","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib119","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PGP.0000000000000543","article-title":"Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer","volume":"38","author":"Sungu","year":"2019","journal-title":"Int J. Gynecol. Pathol."},{"key":"10.1016\/j.biopha.2023.114712_bib120","doi-asserted-by":"crossref","unstructured":"Alter R., Fleming G.F., Stadler W.M., Patnaik A. A phase Ib\/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced\/recurrent endometrial cancer. Journal of clinical oncology (Journal article; Conference proceeding) 2019; 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2663"},{"key":"10.1016\/j.biopha.2023.114712_bib121","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-22-0900","article-title":"Intratumoral heterogeneity and clonal evolution induced by HPV integration","author":"Akagi","year":"2023","journal-title":"Cancer Disco"},{"key":"10.1016\/j.biopha.2023.114712_bib122","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fimmu.2017.00689","article-title":"Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators","volume":"8","author":"Qin","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2023.114712_bib123","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib124","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy targeting HPV16\/18 generates potent immune responses in HPV-associated head and neck cancer","volume":"25","author":"Aggarwal","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2022.05.015","article-title":"Cancer vaccines","volume":"40","author":"Schiller","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.114712_bib126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12935-020-01380-y","article-title":"SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.biopha.2023.114712_bib127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/LGT.0000000000000702","article-title":"Disparities in diagnosis and treatment of cervical adenocarcinoma compared with squamous cell carcinoma: an analysis of the national cancer database, 2004-2017","volume":"27","author":"Smith","year":"2023","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"10.1016\/j.biopha.2023.114712_bib128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2020.01.003","article-title":"Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2023.114712_bib129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biopha.2023.114712_bib130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2023.114712_bib131","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2020.08.026","article-title":"PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer","volume":"159","author":"Rischin","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib132","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12885-018-4764-0","article-title":"'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment","volume":"18","author":"Rotman","year":"2018","journal-title":"BMC Cancer (J. Artic. )"},{"key":"10.1016\/j.biopha.2023.114712_bib133","doi-asserted-by":"crossref","unstructured":"Zhang L., Zhao H., Huang Y., Fang W., Ma Y., Zhang Y. et al. The safety summary of the phase 1a\/b trial of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced malignant tumors. Cancer research (Journal article; Conference proceeding) 2022; 82.","DOI":"10.1158\/1538-7445.AM2022-CT520"},{"key":"10.1016\/j.biopha.2023.114712_bib134","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11912-021-01052-8","article-title":"Immunotherapy in cervical cancer","volume":"23","author":"Mauricio","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2023.114712_bib135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41571-022-00613-5","article-title":"Benefit with cemiplimab in cervical cancer","volume":"19","author":"Romero","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib136","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.114712_bib137","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41467-018-03584-3","article-title":"Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion","volume":"9","author":"Sun","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114712_bib138","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib139","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.114712_bib140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jtho.2020.01.009","article-title":"STING pathway expression identifies NSCLC with an immune-responsive phenotype","volume":"15","author":"Della Corte","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib141","first-page":"13","article-title":"Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers","author":"Amodio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114712_bib142","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102337","article-title":"Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology","volume":"104","author":"Shah","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2023.114712_bib144","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.399","article-title":"Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma","volume":"11","author":"Shi","year":"2021","journal-title":"Clin. Transl. Med"},{"key":"10.1016\/j.biopha.2023.114712_bib145","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Disco"},{"key":"10.1016\/j.biopha.2023.114712_bib146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib147","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","article-title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","volume":"31","author":"Barroso-Sousa","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib148","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114712_bib149","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114712_bib150","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1093\/eurheartj\/ehab249","article-title":"STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases","volume":"42","author":"Pham","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.114712_bib151","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of brcaness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114712_bib152","first-page":"11","article-title":"STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","author":"Ding","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109412","article-title":"Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING","volume":"36","author":"Bruand","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.114712_bib154","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.114712_bib155","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib156","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114712_bib157","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP Inhibitor Olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.114712_bib158","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223005000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223005000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:33:19Z","timestamp":1778247199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223005000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":158,"alternative-id":["S0753332223005000"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114712","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114712"}}